← Human Trials & Peer-Reviewed Studies
Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults.
Plain-language guide to PMID 8180671 (1994): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 patients.
Key Facts
- PMID
- 8180671
- Journal
- European journal of endocrinology
- Year
- 1994
- Study type
- Randomized Controlled Trial
- Authors
- Beshyah SA et al. (6 authors)
- DOI
- 10.1530/eje.0.1300451
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
In the present study the effects of replacement with biosynthetic human growth hormone (GH) in a large group of hypopituitary adults on cardiac structure and function were investigated.
Twenty-nine of the patients had acquired hypopituitarism in adult life, mainly due to pituitary tumours.
Who Took Part
The abstract describes 17 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
What Was Measured
PubMed files the paper under topics including Blood Pressure, Echocardiography, Echocardiography, Doppler, Electrocardiography, Exercise Test, Gonadal Steroid Hormones and Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1994 (European journal of endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.